Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.
For many of these uses, the scientific backing is far weaker than that for GLP-1 drugs. Yet many users extrapolate from the ...
Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback